V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
O M Grbovic1, A D Basso, A Sawai
1Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Abstract:
The Raf family includes three members, of which B-Raf is frequently mutated in melanoma and other tumors. We show that Raf-1 and A-Raf require Hsp90 for stability, whereas B-Raf does not. In contrast, mutated, activated B-Raf binds to an Hsp90-cdc37 complex, which is required for its stability and function. Exposure of melanoma cells and tumors to the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in the degradation of mutant B-Raf, inhibition of mitogen-activated protein kinase activation and cell proliferation, induction of apoptosis, and antitumor activity. These data suggest that activated mutated B-Raf proteins are incompetent for folding in the absence of Hsp90, thus suggesting that the chaperone is required for the clonal evolution of melanomas and other tumors that depend on this mutation. Hsp90 inhibition represents a therapeutic strategy for the treatment of melanoma.
Insights
Heat shock protein 90 (Hsp90) is crucial for the stability of mutated B-Raf in melanoma. Inhibiting Hsp90 degrades mutant B-Raf, offering a potential therapeutic strategy for melanoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The Raf family kinases, including B-Raf, are critical regulators of cell signaling.
- B-Raf mutations are prevalent in melanoma and other cancers, driving tumor growth.
- Heat shock protein 90 (Hsp90) is a molecular chaperone involved in protein folding and stability.
Purpose of the Study:
- To investigate the role of Hsp90 in the stability and function of Raf kinases, particularly mutated B-Raf.
- To evaluate the therapeutic potential of Hsp90 inhibition in melanoma models.
Main Methods:
- Assessing the Hsp90 dependence of Raf-1, A-Raf, and B-Raf isoforms.
- Analyzing the interaction of mutated B-Raf with the Hsp90-cdc37 complex.
- Treating melanoma cells and tumors with the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
- Measuring B-Raf degradation, mitogen-activated protein kinase (MAPK) activation, cell proliferation, apoptosis, and antitumor activity.
Main Results:
- Raf-1 and A-Raf require Hsp90 for stability, while wild-type B-Raf does not.
- Mutated, activated B-Raf binds to the Hsp90-cdc37 complex, which is essential for its stability and function.
- Hsp90 inhibition leads to degradation of mutant B-Raf, suppressed MAPK signaling, reduced cell proliferation, and induced apoptosis.
- Treatment with an Hsp90 inhibitor demonstrated significant antitumor activity in melanoma models.
Conclusions:
- Activated, mutated B-Raf proteins are dependent on Hsp90 for proper folding and stability.
- Hsp90 plays a critical role in the clonal evolution of melanomas dependent on B-Raf mutations.
- Hsp90 inhibition is a promising therapeutic strategy for treating melanoma and other B-Raf-driven tumors.
Related Concept Videos
Molecular Chaperones and Protein Folding
The...
The Unfolded Protein Response
Anaphase Promoting Complex
Export of Misfolded Proteins out of the ER
Regulation of the Unfolded Protein Response
Bacterial Protein Maturation


